Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
AssigneeThe Regents of the University of California
InventorsRanjan Dohil, Jerry Schneider
Life of this patent
Estimating the term…
Abstract
The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Claims22
A method of treating a patient suffering from non-alcoholic fatty liver disease (NAFLD) comprising administering a therapeutically effective amount of cysteamine or a pharmaceutically acceptable salt thereof, or cystamine or a pharmaceutically acceptable salt thereof.
A method of treating a patient suffering from non-alcoholic fatty liver disease (NAFLD) comprising administering to said patient a therapeutically effective amount of a composition comprising cysteamine or a pharmaceutically acceptable salt thereof, or cystamine or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.